Read by QxMD icon Read


shared collection
81 papers 25 to 100 followers
By Alessandro Iadanza Interventional Cardiologist at Siena University Hospital
Brett Oestreich, Sergey Gurevich, Selcuk Adabag, Rosemary Kelly, Gregory Helmer, Ganesh Raveendran, Demetris Yannopoulos, Timinder Biring, Santiago Garcia
BACKGROUND: Tissue edema and inflammation, which occur at the device landing zone during valve deployment, may contribute to the pathophysiology of conduction abnormalities after transcatheter aortic valve replacement (TAVR). We hypothesized that exposure to glucocorticoids prior to TAVR will reduce the incidence of conduction abnormalities requiring PPM implantation after TAVR. METHODS: We included 167 consecutive patients treated with TAVR at the Minneapolis VA Medical Center and University of Minnesota...
July 18, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Joseph E Bavaria, Carl L Tommaso, Ralph G Brindis, John D Carroll, G Michael Deeb, Ted E Feldman, Thomas G Gleason, Eric M Horlick, Clifford J Kavinsky, Dharam J Kumbhani, D Craig Miller, A Allen Seals, David M Shahian, Richard J Shemin, Thoralf M Sundt, Vinod H Thourani
No abstract text is available yet for this article.
July 18, 2018: Journal of the American College of Cardiology
Rajkumar Doshi
No abstract text is available yet for this article.
July 20, 2018: EuroIntervention
Russell James Everett, Marie-Annick Clavel, Philippe Pibarot, Marc Richard Dweck
No abstract text is available yet for this article.
July 20, 2018: Heart: Official Journal of the British Cardiac Society
Erwan Salaun, Marie-Annick Clavel, Josep Rodés-Cabau, Philippe Pibarot
The main limitation of bioprosthetic valves is their limited durability, which exposes the patient to the risk of aortic valve reintervention. Transcatheter aortic valve implantation (TAVI) is considered a reasonable alternative to surgical aortic valve replacement (SAVR) in patients with intermediate or high surgical risk. TAVI is now rapidly expanding towards the lower risk populations. Although the results of midterm durability of the transcatheter bioprostheses are encouraging, their long-term durability remains largely unknown...
August 2018: Heart: Official Journal of the British Cardiac Society
Rebecca T Hahn, Alina Nicoara, Samir Kapadia, Lars Svensson, Randolph Martin
Transcatheter aortic valve replacement has become an accepted alternative to surgery for patients with severe, symptomatic aortic stenosis who are inoperable or are at high surgical risk. Recent trials support the use of transcatheter aortic valve replacement also in patients at intermediate risk, and ongoing trials are assessing appropriateness in other patient groups. The authors review the key anatomic features integral to the transcatheter aortic valve replacement procedure and the echocardiographic imaging required for preprocedural, intraprocedural, and postprocedural assessment...
April 2018: Journal of the American Society of Echocardiography
Volkmar Falk, Helmut Baumgartner, Jeroen J Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Muñoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano
No abstract text is available yet for this article.
October 1, 2017: European Journal of Cardio-thoracic Surgery
Catherine M Otto
No abstract text is available yet for this article.
January 2018: Heart: Official Journal of the British Cardiac Society
Oscar Millan-Iturbe, Fadi J Sawaya, Jacob Lønborg, Danny H F Chow, Gintautas Bieliauskas, Thomas Engstrøm, Lars Søndergaard, Ole De Backer
Transcatheter aortic valve replacement (TAVR) has become an established therapeutic option for patients with symptomatic, severe aortic stenosis. The optimal treatment strategy for concomitant coronary artery disease (CAD) has not been tested prospectively in a randomized clinical trial. This study aimed to describe the degree of CAD, revascularization strategies, and long-term clinical outcomes in a large-scale all-comers TAVR-population. Nine hundred and forty-four consecutive patients underwent TAVR. Obstructive CAD was reported in 224 patients (23...
December 7, 2017: Catheterization and Cardiovascular Interventions
Björn Redfors, Philippe Pibarot, Linda D Gillam, Daniel Burkhoff, Jeroen J Bax, Brian R Lindman, Robert O Bonow, Patrick T O'Gara, Martin B Leon, Philippe Généreux
Aortic stenosis is 1 of the most common heart valve diseases among adults. When symptoms develop, prognosis is poor, and current guidelines recommend prompt aortic valve replacement. Depending of the severity of the aortic stenosis and the presence of concomitant heart disease and medical comorbidities, stress testing represents a reasonable strategy to help better risk stratify asymptomatic patients. The present report provides a comprehensive review of the current available data on stress testing in aortic stenosis and subsequently summarizes its potential for guiding the optimal timing of aortic valve replacement...
May 16, 2017: Circulation
Rick A Nishimura, Catherine M Otto, Robert O Bonow, Blase A Carabello, John P Erwin, Lee A Fleisher, Hani Jneid, Michael J Mack, Christopher J McLeod, Patrick T O'Gara, Vera H Rigolin, Thoralf M Sundt, Annemarie Thompson
No abstract text is available yet for this article.
June 20, 2017: Circulation
Marie-Annick Clavel, Ian G Burwash, Philippe Pibarot
Up to 40% of patients with aortic stenosis (AS) harbor discordant Doppler-echocardiographic findings, the most common of which is the presence of a small aortic valve area (≤1.0 cm2 ) suggesting severe AS, but a low gradient (<40 mm Hg) suggesting nonsevere AS. The purpose of this paper is to present the role of multimodality imaging in the diagnostic and therapeutic management of this challenging entity referred to as low-gradient AS. Doppler-echocardiography is critical to determine the subtype of low-gradient AS: that is, classical low-flow, paradoxical low-flow, or normal-flow...
February 2017: JACC. Cardiovascular Imaging
Catherine M Otto, Dharam J Kumbhani, Karen P Alexander, John H Calhoon, Milind Y Desai, Sanjay Kaul, James C Lee, Carlos E Ruiz, Christina M Vassileva
No abstract text is available yet for this article.
March 14, 2017: Journal of the American College of Cardiology
Guillaume Marquis-Gravel, Björn Redfors, Martin B Leon, Philippe Généreux
Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis. The only treatment shown to improve survival is aortic valve replacement; however, before symptoms occur, aortic stenosis is preceded by a silent, latent phase characterized by a slow progression at the molecular, cellular, and tissue levels. In theory, specific medical therapy should halt aortic stenosis progression, reduce its hemodynamic repercussions on left ventricular function and remodeling, and improve clinical outcomes...
November 29, 2016: Circulation
Giuseppe Tarantini, Marco Mojoli, Marina Urena, Alec Vahanian
Atrial fibrillation (AF) is a common arrhythmia in patients with aortic stenosis. When these patients are treated medically or by surgical aortic valve replacement, AF is associated with increased risk of adverse events including death. Growing evidence suggests a significant impact of AF on outcomes also in patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). Conversely, limited evidence is available regarding the optimal management of this condition. This review aims to summarize prevalence, pathophysiology, prognosis, and treatment of AF in patients undergoing TAVI...
May 1, 2017: European Heart Journal
Philippe Généreux, Gregg W Stone, Patrick T O'Gara, Guillaume Marquis-Gravel, Björn Redfors, Gennaro Giustino, Philippe Pibarot, Jeroen J Bax, Robert O Bonow, Martin B Leon
Aortic stenosis (AS) is one of the most common valvular diseases encountered in clinical practice. Current guidelines recommend aortic valve replacement (AVR) when the aortic valve is severely stenotic and the patient is symptomatic; however, a substantial proportion of patients with severe AS are asymptomatic at the time of first diagnosis. Although specific morphological valve features, exercise testing, stress imaging, and biomarkers can help to identify patients with asymptomatic severe AS who may benefit from early AVR, the optimal management of these patients remains uncertain and controversial...
May 17, 2016: Journal of the American College of Cardiology
Seung-Pyo Lee, Whal Lee, Joo Myung Lee, Eun-Ah Park, Hyung-Kwan Kim, Yong-Jin Kim, Dae-Won Sohn
PURPOSE: To assess whether native T1 mapping provides noninvasive estimation of diffuse myocardial fibrosis and whether it correlates with subclinical myocardial dysfunction in asymptomatic patients with aortic stenosis (AS). MATERIALS AND METHODS: The local institutional review board approved the study, and all patients gave informed consent. Eighty asymptomatic patients with moderate or severe AS and normal left ventricular (LV) ejection fraction (mean age, 67 years; range, 31-81 years) and 15 sex-matched control subjects (mean age, 33 years; range, 23-41 years) were prospectively enrolled...
February 2015: Radiology
2016-10-21 05:41:14
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"